China Plans To Amend Nearly 10 Pharma Regs This Year
This article was originally published in PharmAsia News
China's State FDA plans to launch new GMP guidelines this year to better ensure drug quality, including raw materials registration that will tighten recording requirements, according to a recent SFDA conference
You may also be interested in...
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.